SCOPUS 정보 검색 플랫폼

British Journal of Cancer

Volumn 84, Issue 9, 2001, Pages 1146-1149

Adjuvant interferon alpha 2b in high risk melanoma - The scottish study

(6) Cameron, D A a Cornbleet, M C a Mackie, R M b Hunter, J A A c Gore, M d Hancock, B e

a WESTERN GENERAL HOSPITAL (United Kingdom)

b WESTERN INFIRMARY (United Kingdom)

c ROYAL INFIRMARY OF EDINBURGH (United Kingdom)

d ROYAL MARSDEN HOSPITAL (United Kingdom)

e WESTON PARK HOSPITAL (United Kingdom)

Author keywords

Adjuvant; Interferon; Melanoma; Scottish trial

Indexed keywords

ALPHA2B INTERFERON;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEVER; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; MULTICENTER STUDY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; UNITED KINGDOM;

ADULT; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; MELANOMA; SKIN NEOPLASMS;

EID: 0035805053 PISSN: 00070920 EISSN: None Source Type: Journal
DOI: 10.1054/bjoc.2000.1623 Document Type: Article

Times cited : (148)

References (10)

1
- 0001034265
- Evaluation of efficacy of adjuvant r1FN alpha 2a in melanoma patients with regional node metastases
- (1995) Proc Annu Meet Am Soc Clin Oncol , vol.14
- Cascinelli, N.¹

2
- 0004901966
- Data presented. Melanoma, London
- (1999) 3rd International Conference on Adjuvant Therapy of Malignant
- Cascinelli, N.¹

3
- 7144228601
- Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases
- French Co-operative Group on Melanoma. [see comments]
- (1998) Lancet , vol.351 , pp. 1905-1910
- Grob, J.J.¹ Dreno, B.² De la Salmoniere, P.³ Delaunay, M.⁴ Cupissol, D.⁵ Guillot, B.⁶ Souteyrand, P.⁷ Sassolas, B.⁸ Cesarini, J.P.⁹ Lionnet, S.L.¹⁰ Chastang, C.¹¹ Bonerandi, J.J.¹²

4
- 0030030347
- Interferon Alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Co-operative Oncology Group Trial EST 1684
- (1996) J Clin Oncol , vol.14 , pp. 7-17
- Kirkwood, J.M.¹ Strawderman, M.H.² Ernstoff, M.S.³ Smith, T.J.⁴ Borden, E.C.⁵ Blum, R.H.⁶

5
- 0034088027
- High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190
- (2000) J Clin Oncol , vol.18 , pp. 2444-2458
- Kirkwood, J.M.¹ Ibrahim, J.G.² Sondak, V.K.³ Richards, J.⁴ Flaherty, L.E.⁵ Ernstoff, M.S.⁶ Smith, T.J.⁷ Rao, U.⁸ Steele, M.⁹ Blum, R.H.¹⁰

6
- 0001858085
- Relapse-free and overall survival are significantly prolonged by high-dose IFN alpha 2b (HDI) compared to vaccine GM2-KLH with QS21 (GMK, Progenics) for high-risk resected stage IIB-III melanoma: Results of the Intergroup Phase III study E1694/S9512/C503801
- abstract
- (2000) Eur J Cancer , vol.11 , Issue.SUPPL. 4 , pp. 40
- Kirkwood, J.M.¹ Ibrahim, J.² Sondak, V.K.³ Sosman, J.A.⁴ Ernstoff, M.S.⁵

7
- 0022633528
- Interferons in the treatment of malignant melanoma. A review of recent trials
- (1986) Cancer , vol.57 , pp. 1675-1677
- Legha, S.S.¹

8
- 0026603297
- Cutaneous malignant melanoma, Scotland, 1979-89
- The Scottish Melanoma Group
- (1992) Lancet , vol.339 , pp. 971-975
- Mackie, R.¹ Hunter, J.A.² Aitchison, T.C.³ Hole, D.⁴ Mclaren, K.⁵ Rankin, R.⁶ Blessing, K.⁷ Evans, A.T.⁸ Hutcheon, A.W.⁹ Jones, D.H.¹⁰

9
- 7144264391
- Adjuvant interferon Alfa-2a treatment in resected primary stage II cutaneous melanoma
- (1998) J Clin Oncol , vol.16 , pp. 1425-1429
- Pehamberger, H.¹ Soyer, H.P.² Steiner, A.³ Kofler, R.⁴ Binder, M.⁵ Mischer, P.⁶ Pachinger, W.⁷ Auböck, J.⁸ Fritsch, P.⁹ Kerl, H.¹⁰ Wolff, K.¹¹

10
- 0030912391
- Postsurgical adjuvant therapy for melanoma. Evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up
- (1997) Cancer , vol.79 , pp. 2354-2360
- Rusciani, L.¹ Petraglia, S.² Alotto, M.³ Calvieri, S.⁴ Vezzoni, G.⁵

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.